Sacubitril/Valsartan Versus Enalapril in Chagas Cardiomyopathy With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis

View at publisher Summarise with VIRAT
Authors: Shaikh Muhammad Daniyal, Sabula Tabish, Muhammad Burhan, Amna Noor, Amna Amir Jalal, Ayan Khalid, Shaikh Muhammad Sharjeel, Isbah Gul, Muhammad Hasan Siddiqui, Danish Ali Ashraf, Ibrahim Nagmeldin Hassan
Cited by: 0
References: 37

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Chagas cardiomyopathy is a leading cause of heart failure (HF) with reduced ejection fraction (HFrEF) in endemic regions, yet patients with this distinct etiology have been underrepresented in pivotal HF trials. This creates significant uncertainty regarding the efficacy of guideline-directed therapies, including sacubitril-valsartan, in this population. PubMed, Cochrane (CENTRAL), Scopus, and Embase were searched from inception to December 17, 2025, for randomized controlled trials comparing sacubitril-valsartan to enalapril in patients with HFrEF due to Chagas cardiomyopathy. Primary outcomes were the composite endpoint of cardiovascular mortality or HF hospitalization, all-cause mortality, and individual components of the composite endpoint. Secondary outcomes included the percentage change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) and adverse events. Three randomized controlled trials (n = 1225) patients were included. Sacubitril-valsartan did not significantly reduce the risk of the primary composite endpoint (risk ratio: 0.92; 95% confidence interval [CI]: 0.81-1.05; P = 0.216) or all-cause mortality (risk ratio: 0.96; 95% CI: 0.79-1.17; P = 0.691) compared to enalapril. However, it resulted in a significantly greater reduction in NT-proBNP levels (mean difference: -31.00%; 95% CI: -51.40 to -10.60; P < 0.01). The risks of renal dysfunction, symptomatic hypotension, and hyperkalemia were comparable between the 2 treatments. In patients with HFrEF due to Chagas cardiomyopathy, sacubitril-valsartan did not significantly improve hard clinical outcomes compared to enalapril but was associated with a substantially greater reduction in NT-proBNP and a similar safety profile. These findings underscore the unique pathophysiology of this disease and highlight the critical need for large, long-term outcome trials specifically powered for this neglected population.

Fields of Study & Subjects

Heart Failure Treatment and Management Trypanosoma species research and implications Cardiac Fibrosis and Remodeling

Publication details

Journal / source
Cardiology in Review
Publication date
2 April 2026
Language
EN